Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radarMarket Watch • 02/07/24
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung CancerBusiness Wire • 02/07/24
Bristol Myers Squibb Named One of America's Most JUST Companies by JUST Capital and CNBCBusiness Wire • 02/05/24
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 StudyBusiness Wire • 02/05/24
Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/02/24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023Business Wire • 02/02/24
Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q4 EarningsZacks Investment Research • 01/30/24
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)Business Wire • 01/30/24